Tao Xie

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing
    Tao Xie
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, CA, USA Electronic address
    Genomics 104:234-41. 2014
  2. pmc A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations
    Tao Xie
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
    PLoS ONE 7:e42001. 2012
  3. ncbi request reprint A survey of cancer cell lines reveals highly structured and hierarchical relationships within and between DNA and mRNA that may be the result of selection
    Tao Xie
    Rosetta Inpharmatics LLC, Seattle Washington, USA
    OMICS 14:91-7. 2010
  4. pmc Clinicopathologic and gene expression parameters predict liver cancer prognosis
    Ke Hao
    Merck Research Laboratories, Boston, MA, USA
    BMC Cancer 11:481. 2011
  5. ncbi request reprint Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
    Kai Wang
    1 Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA 2
    Nat Genet 46:573-82. 2014
  6. ncbi request reprint Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
    Kai Wang
    Oncology Research Unit, Pfizer Inc, San Diego, CA, USA
    Hepatology 58:706-17. 2013

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing
    Tao Xie
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, CA, USA Electronic address
    Genomics 104:234-41. 2014
    ..These results suggest that somatic alterations may play an important role in driving the development of colorectal cancer metastasis and present challenges and opportunities when considering the choice of treatment...
  2. pmc A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations
    Tao Xie
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
    PLoS ONE 7:e42001. 2012
    ..These results reinforce the non-random nature of somatic CNAs in stage-II/III CRC and highlight loci and genes that may play an important role in driving the development and outcome of this disease...
  3. ncbi request reprint A survey of cancer cell lines reveals highly structured and hierarchical relationships within and between DNA and mRNA that may be the result of selection
    Tao Xie
    Rosetta Inpharmatics LLC, Seattle Washington, USA
    OMICS 14:91-7. 2010
    ..Given that the cohort includes many tissue types, our observations may identify a common and important underlying structure present in human tumors...
  4. pmc Clinicopathologic and gene expression parameters predict liver cancer prognosis
    Ke Hao
    Merck Research Laboratories, Boston, MA, USA
    BMC Cancer 11:481. 2011
    ..However, there has been little systematic effort to compare the performance of these two types of predictors or combine them in a comprehensive model...
  5. ncbi request reprint Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
    Kai Wang
    1 Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA 2
    Nat Genet 46:573-82. 2014
    ..These findings illustrate a multidimensional and comprehensive genomic landscape that highlights the molecular complexity of gastric cancer and provides a road map to facilitate genome-guided personalized therapy...
  6. ncbi request reprint Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
    Kai Wang
    Oncology Research Unit, Pfizer Inc, San Diego, CA, USA
    Hepatology 58:706-17. 2013
    ..We further credentialed two candidate driver genes (BCL9 and MTDH) from the recurrent focal amplification peaks and showed that they play a significant role in HCC growth and survival...